How does belimumab compare to anifrolumab for treating lupus nephritis?
Belimumab and anifrolumab are biologic therapies used for systemic lupus erythematosus (SLE), but they differ in their approval and evidence for treating lupus nephritis (LN). Belimumab is approved for LN, while anifrolumab is not. A 2023 network meta-analysis ranked belimumab as the most effective biologic for achieving complete renal remission in LN, outperforming anifrolumab 10. A 2026 meta-analysis also found that belimumab has stronger evidence for LN, though direct head-to-head trials are lacking 19.
What the research says
A 2023 network meta-analysis of 10 randomized controlled trials involving 2,148 patients compared several biologics for LN. For the primary outcome of complete renal remission, belimumab ranked highest, followed by anifrolumab (900+300 mg dose), and was significantly superior to placebo (odds ratio 1.75, 95% CI 1.13-2.70) and to anifrolumab 300 mg (odds ratio 3.27, 95% CI 1.05-10.18) 10. This suggests belimumab is more effective than anifrolumab for treating LN.
A 2026 meta-analysis of 7 RCTs with 4,332 patients indirectly compared belimumab and anifrolumab for SLE and LN. It confirmed that belimumab is approved for both SLE and LN, whereas anifrolumab is not approved for LN and has only been studied in one phase II trial for LN 19. The analysis evaluated endpoints like complete renal response, renal event-free survival, and safety, but did not find a statistically significant difference between the two drugs for LN outcomes, likely due to limited data for anifrolumab 19.
Overall, the evidence indicates that belimumab has more robust support for LN, while anifrolumab's role remains investigational. No direct head-to-head trials exist, so comparisons rely on indirect analyses 1910.
What to ask your doctor
- Is belimumab a good option for my lupus nephritis, given its approval and evidence for complete renal remission?
- What does the research say about anifrolumab for lupus nephritis, and is it available through clinical trials?
- How do the side effect profiles of belimumab and anifrolumab compare, especially regarding infections?
- Would combining either biologic with my current treatment (e.g., mycophenolate or cyclophosphamide) be appropriate?
- Are there any ongoing trials for anifrolumab in lupus nephritis that I might consider?
This question is drawn from common patient questions about Rheumatology and answered using cited medical research. We do not provide individualized advice.